US distribution will be handled by Vitruvias and Bright Future will be responsible for China and other agreed upon Asian territories.
The products will be manufactured by Bright Future's newly constructed unit at its Hong Kong site specifically designed for producing products in regulated markets.
Vitruvias Therapeutics is a generic pharmaceutical company which utilises domestic and international partnerships to develop, manufacture, and market generic products.
Founded in the southern US in 2013, the company's primary focus is on products in the generic sterile injectable market, semi-solid market, and selected high-value oral solids.
The company currently markets several generic products in the US The company received its first approval in September 2017 and anticipates several additional ANDA applications will be filed during 2019.
Headquartered in Hong Kong, Bright Future Group is a leading pharmaceutical company committed to developing generic medical solutions since 1993.
Currently, the company is the largest PIC/S GMP certified pharmaceutical manufacturer in Hong Kong.
With years of development, it has also established subsidiary plants in Hong Kong, Mainland China, the USA and Germany.
Pursuing its long-term corporate vision, 7,000 employees dedicate themselves to the research and development, manufacturing and commercialization of generic medicines, health supplements and daily necessities worldwide.
It focuses on the treatment of disorders for patients in the areas of dermatology, orthopedics, respiratory, pediatrics, geriatric and gynecology.
Bright Future Group has international R and D teams in Hong Kong, New York, as well as Haikou and Suzhou in China to support its network.
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling
Sandoz's Tyruko (natalizumab-sztn) gains FDA approval as first biosimilar for relapsing MS
Nephron Pharmaceutical names new chief procurement officer
Lupin Pharmaceuticals launches Tiotropium Bromide Inhalation Powder, 18mcg/capsule in US